SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (316)6/3/1999 5:17:00 PM
From: Abuckatatime  Respond to of 804
 
NEJM review article discusses thalidomide in treatment of AIDS wasting - Drug Therapy: Treatments for Wasting in Patients with the Acquired Immunodeficiency Syndrome. N Engl J Med. 1999 Jun 3;340(22):1740-1750. Nothing really new but good exposure nonetheless. The results of these 4 studies are briefly summarized:

ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

ncbi.nlm.nih.gov



To: Biomaven who wrote (316)6/4/1999 12:42:00 AM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 804
 
Indeed, some of the *river water* may end up in CELG *lake*.

Giving the growing generic-R presence on market, (+)-R partner will be nice news.



HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News